Prognostic analysis of 8 patients with hepatic adenoma undergoing allogeneic hematopoietic stem cell transplantation
10.3760/cma.j.cn121090-20240329-00120
- VernacularTitle:异基因造血干细胞移植治疗合并肝腺瘤血液病患者8例临床分析
- Author:
Yun HE
1
;
Zhengli XU
;
Rui MA
;
Jing LIU
;
Yuanyuan ZHANG
;
Meng LYU
;
Xiaodong MO
;
Chenhua YAN
;
Yuqian SUN
;
Xinyu ZHANG
;
Yu WANG
;
Xiaohui ZHANG
;
Xiaojun HUANG
;
Lanping XU
Author Information
1. 北京大学人民医院血液科，北京大学血液病研究所，国家血液系统疾病临床医学研究中心，造血干细胞移植治疗血液病北京市重点实验室，北京 100044
- Keywords:
Adenoma, liver cell;
Allogeneic hematopoietic stem cell transplantation;
Aplastic anemia;
Myelodysplastic syndrome
- From:
Chinese Journal of Hematology
2024;45(9):816-820
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the safety of patients with hepatic adenoma undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) .Methods:A retrospective analysis of the clinical characteristics and prognosis of eight patients with hepatic adenoma who underwent allo-HSCT in the Hematology Department of Peking University People’s Hospital from January 2010 to March 2024 was conducted.Results:Of the eight patients who underwent allo-HSCT with hepatic adenoma, one patient was considered MDS-h transfusion-dependent and seven had aplastic anemia. The median age of the patients was 23 years (13-48 years). The median time from the diagnosis of AA or MDS to transplantation was 14 years (6-24 years), whereas the median time from taking androgens to diagnosing hepatic adenoma was 9 years (5-13 years). Six cases underwent haplo-HSCT, one case underwent matched unrelated donor HSCT, and one case underwent matched related donor HSCT. All patients achieved neutrophil engraftment at a median time of 11.5 days (11-20 days) and PLT engraftment within 60 days at a median of 19 days (10-37 days) after haplo-HSCT. Moreover, seven patients developed CMV anemia after transplantation, three patients had hemorrhagic cystitis, and two patients developed acute GVHD. During and after transplantation, eight patients did not show severe liver function damage or rupture of hepatic adenoma. In relation to imaging size, four patients showed varying degrees of reduction in hepatic adenoma size after transplantation, whereas four patients did not show significant changes in hepatic adenoma size after transplantation. The median follow-up time was 540.5 (30-2 989) days. Of the eight patients, six survived and two died. Furthermore, no direct correlation was observed between death and hepatic adenoma.Conclusion:Patients with hepatic adenomas undergoing allo-HSCT are not contraindications for transplantation, which will not increase transplant-related mortality.
